{"entity":{"id":"nct05309421","kind":"trial","name":"A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma","aka":[],"tldr":"A phase 2 trial of Pembrolizumab in melanoma, run by Evaxion Biotech A/S, active and no longer recruiting.","summary":"A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma is a phase 2 interventional study registered as NCT05309421 by Evaxion Biotech A/S, with 17 participants enrolled, started 2022-09-19 and due to reach its primary completion in 2025-09-30. Interventions recorded: EVX-01, Pembrolizumab 25 MG/ML. Conditions listed: Melanoma Stage IV, Unresectable Melanoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05309421","url":"https://clinicaltrials.gov/study/NCT05309421"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":["evaxion"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05309421","phase":"2","setting":"An Open Label, Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Checkpoint Inhibitor Treatment naïve Adults With Unresectable or Metastatic Melanoma","sponsor":"Evaxion Biotech A/S","enrolled":17,"outcomes":[]},"route":"/trials/nct05309421/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"evaxion","kind":"company","name":"Evaxion","route":"/companies/evaxion/"}]}}